CY1117469T1 - Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου - Google Patents

Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου

Info

Publication number
CY1117469T1
CY1117469T1 CY20161100219T CY161100219T CY1117469T1 CY 1117469 T1 CY1117469 T1 CY 1117469T1 CY 20161100219 T CY20161100219 T CY 20161100219T CY 161100219 T CY161100219 T CY 161100219T CY 1117469 T1 CY1117469 T1 CY 1117469T1
Authority
CY
Cyprus
Prior art keywords
disorders
inhibitors
indazolis
motion
beta
Prior art date
Application number
CY20161100219T
Other languages
English (en)
Inventor
Maria Alessandra Alisi
Nicola Cazzolla
Patrizia Dragone
Guido Furlotti
Caterina Maugeri
Rosella Ombrato
Original Assignee
Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A.
Publication of CY1117469T1 publication Critical patent/CY1117469T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις 1Η-ινδαζολη-3-καρβοξαμίδης που έχουν τον ακόλουθο γενικό χημικό τύπο (I) που χρησιμοποιούνται ως αναστολείς της κινάσης 3 βήτα της συνθάσης του γλυκογόνου (GSK-3β) και στην χρήση τους για την αντιμετώπιση διαταραχών που σχετίζονται με την GSK-3β όπως είναι, για παράδειγμα, (i) οι διαταραχές ανοχής στην ινσουλίνη, (ii) νευροεκφυλιστικές παθήσεις, (iii) διαταραχές της διάθεσης, (iv) σχιζοφρενικές διαταραχές, (ν) καρκινικές διαταραχές, (vi) φλεγμονή, (vii) διαταραχές κατάχρησης ουσιών, (viii) επιληψίες, και (ix) νευροπαθητικός πόνος.
CY20161100219T 2012-02-21 2016-03-15 Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου CY1117469T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156292 2012-02-21
EP13704910.2A EP2817302B1 (en) 2012-02-21 2013-02-07 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (1)

Publication Number Publication Date
CY1117469T1 true CY1117469T1 (el) 2017-04-26

Family

ID=47739223

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100219T CY1117469T1 (el) 2012-02-21 2016-03-15 Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου

Country Status (27)

Country Link
US (3) US9611249B2 (el)
EP (1) EP2817302B1 (el)
JP (1) JP6141331B2 (el)
KR (1) KR20140130124A (el)
CN (1) CN104093712B (el)
AR (1) AR090086A1 (el)
AU (1) AU2013224302B2 (el)
BR (1) BR112014018655B1 (el)
CA (1) CA2860250C (el)
CY (1) CY1117469T1 (el)
DK (1) DK2817302T3 (el)
EA (1) EA024939B1 (el)
ES (1) ES2564961T3 (el)
GE (1) GEP20166489B (el)
HK (1) HK1203930A1 (el)
HR (1) HRP20160125T1 (el)
HU (1) HUE026893T2 (el)
IL (1) IL233824A (el)
ME (1) ME02353B (el)
MX (1) MX351287B (el)
PL (1) PL2817302T3 (el)
RS (1) RS54567B1 (el)
SG (2) SG11201403602WA (el)
SI (1) SI2817302T1 (el)
SM (1) SMT201600053B (el)
UA (1) UA112564C2 (el)
WO (1) WO2013124158A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54539B1 (en) * 2012-02-21 2016-06-30 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. USE OF 1H-INDASOL-3-CARBOXAMIDE COMPOUNDS AS A 3-BETA GLYCOGEN SYNTHETASE KINASE INHIBITOR
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3119393A4 (en) 2014-03-20 2018-02-28 Samumed, LLC 5-substituted indazole-3-carboxamides and preparation and use thereof
ES2913929T3 (es) * 2016-06-08 2022-06-06 Glaxosmithkline Ip Dev Ltd Compuestos químicos como inhibidores de la ruta de ATF4
CA3091913A1 (en) 2018-02-23 2019-08-29 Samumed, Llc 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
GEP20227437B (en) * 2018-05-07 2022-11-10 Acraf 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US11510904B2 (en) 2018-06-05 2022-11-29 Actuate Therapeutics Inc. Methods of treating malignant lymphoproliferative disorders
SG11202102406XA (en) 2018-09-13 2021-04-29 Bristol Myers Squibb Co Indazole carboxamides as kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010174A1 (en) 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
JP2006502133A (ja) * 2002-08-10 2006-01-19 アステックス、セラピューティックス、リミテッド サイクリン依存キナーゼ（ｃｄｋ）インヒビターとしての３−（カルボニル）１ｈ−インダゾール化合物
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
EP1692939A1 (en) * 2005-02-19 2006-08-23 Bayer CropScience S.A. Pesticidal substituted piperidines
AU2008262038A1 (en) 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators

Also Published As

Publication number Publication date
HRP20160125T1 (hr) 2016-03-11
SG10201701649YA (en) 2017-04-27
EA201491449A1 (ru) 2014-11-28
AR090086A1 (es) 2014-10-15
BR112014018655A2 (el) 2017-06-20
AU2013224302B2 (en) 2017-03-30
ES2564961T3 (es) 2016-03-30
US20170174657A1 (en) 2017-06-22
MX351287B (es) 2017-10-09
ME02353B (me) 2016-06-20
US20170157121A1 (en) 2017-06-08
DK2817302T3 (en) 2016-03-21
IL233824A0 (en) 2014-09-30
EP2817302B1 (en) 2015-12-30
AU2013224302A1 (en) 2014-07-17
CN104093712A (zh) 2014-10-08
GEP20166489B (en) 2016-06-10
JP6141331B2 (ja) 2017-06-07
KR20140130124A (ko) 2014-11-07
US10160746B2 (en) 2018-12-25
HUE026893T2 (en) 2016-07-28
CA2860250C (en) 2020-11-10
HK1203930A1 (zh) 2015-11-06
RS54567B1 (en) 2016-06-30
MX2014009297A (es) 2014-08-27
CA2860250A1 (en) 2013-08-29
EA024939B1 (ru) 2016-11-30
JP2015506993A (ja) 2015-03-05
SMT201600053B (it) 2016-04-29
UA112564C2 (uk) 2016-09-26
CN104093712B (zh) 2016-11-09
PL2817302T3 (pl) 2016-06-30
IL233824A (en) 2016-09-29
BR112014018655B1 (pt) 2022-02-08
US9611249B2 (en) 2017-04-04
BR112014018655A8 (pt) 2017-07-11
SI2817302T1 (sl) 2016-03-31
WO2013124158A1 (en) 2013-08-29
EP2817302A1 (en) 2014-12-31
SG11201403602WA (en) 2014-07-30
US20150057294A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CY1117469T1 (el) Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου
CY1117467T1 (el) Χρηση των ενωσεων 1η-ινδαζολης-3- καρβοξαμιδης ως αναστολεις της κινασης 3 β της συνθασης γλυκογονου
CY1123811T1 (el) Κρυσταλλικη μορφη αναστολεα pde4
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
BR112015027951A2 (pt) arilquinazolinas
BR112015000399A2 (pt) derivados de pirazolil pirimidina
EA201301183A1 (ru) Гетероциклические соединения в качестве ингибиторов киназ
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
CR20150633A (es) Derivados del bipirazol como inhibidores jak
EA201391106A1 (ru) Новые гетероциклические производные
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
GT201500054A (es) Moléculas de enlace a il-18
ECSP14013188A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
EA201590504A1 (ru) Индолкарбоксамидные производные и их применение
NI201200066A (es) Métodos de síntesis y purificación de compuestos heteroarilos
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
BR112015009649A2 (pt) composto de triazolo
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac
CO7240362A2 (es) Molécula de unión il-6
DOP2019000047A (es) Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres
CY1125060T1 (el) Καινουρια παραγωγα βενζαμιδης ως ρυθμιστες των ppar-γαμμα
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.